NCT07033585Active, not recruitingPhase 2/3
Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
Source: ClinicalTrials.gov · Last updated 27 Aug 2026
Brief summary (registry, in English)
Use Dapagliflozin 10 mg, Saxagliptin 5 mg, Metformin 500 mg treat type 2 diabetes patients with controlled cancers
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 600 (estimated)
- First submitted
- 16 Jun 2025
- Start date
- 15 Jun 2026
- Primary completion date
- 18 Oct 2026
- Lead sponsor
- Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
- Diseases
- Type 2 diabetes
- NCT number
- NCT07033585
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 600
- From 15 Jun 2026 to the primary completion date, 18 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 8\. Serious Risks or Serious Adverse Events of the drug product
- 9\. The prohibition of drug products
Other illness
- 1\. Uncontrolled cancers
- 4\. The patients with other serious intercurrent illness or infectious diseases
- 6\. Serious Allergy to Drugs
Other
- 2\. Pregnancy
- 3\. Breast-feeding
- 5\. The participating patients have serious side effects.
- 7\. Thrombus or Bleed Tendency
- 10\. Have no therapeutic effects
Who the study is looking for
- 1\. Clinical diagnosis of type 2 diabetes
- 2\. Controlled cancers
- 3\. Suitable for enough blood-drawing
- 4\. Random and double blind
- 5\. Measurable disease
- 6\. Adequate organ functions
- 7\. Adequate performance status
- 8\. Age 24 years old and over
- 9\. Sign an informed consent form
- 10\. Receive blood-drawing
Criteria the registry did not label
- Select 600 type 2 diabetes patients with controlled cancers.
- Dosage Duration at least 90 days
Age in the registry: 24 years to 64 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medicine Invention Design, Inc. - IORG0007849 - NPI 1023387701 Coordinator of this site? Confirm its status | Rockville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.